First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors

被引：0
|
作者：
Daud, Adil
Albany, Costantine
Velcheti, Vamsidhar
Hauke, Ralph J.
Ahnert, Jordi Rodon
Karp, Daniel D.
Tsimberidou, Apostolia Maria
Cohen, Julia Wanda
Schmidt, Emmett V.
Wang, Jieyi
Chan, C. Hubert
Fu, Siqing
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Horizon Oncol & Res Ctr, Lafayette, IN USA
[3] NYU, New York, NY USA
[4] Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[5] Nebraska Canc Specialists, Omaha, NE USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Merck Co Inc, Rahway, NJ USA
[8] Lyvgen Biopharma, Shanghai, Peoples R China
[9] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2525
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.
    Fu, Siqing
    Harb, Wael A.
    Patel, Sapna Pradyuman
    Lu, Charles
    Halperin, Daniel M.
    Hsu, Yi Hsin
    Shi, Naiyi
    Yamamura, Yuko
    Tang, Tony
    Jiang, Lynn
    Su, Fusheng
    Cohen, Julia Wanda
    Schmidt, Emmett V.
    Wang, Jieyi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.
    Daud, Adil
    Velcheti, Vamsidhar
    Bever, Katherine M.
    Chow, Warren Allen
    Albany, Costantine
    Hauke, Ralph J.
    Tsai, Katy K.
    Chisamore, Michael Jon
    Wang, Jieyi
    Chan, C. Hubert
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] An open label, phase 1b/2 trial of LVGN6051 (4-1BB agonistic antibody) combined with anlotinib for refractory soft tissue sarcoma (STS)
    Zhou, Yan
    Li, Xianan
    Li, Linqing
    Zhang, Peng
    Ye, Zhaoming
    Li, Binghao
    Chen, Yong
    Zhang, Jian
    Ding, Xiaomin
    Zhang, Qunzi
    Tan, Qiyuan
    Zhang, Chunhao
    Zhang, Zhichang
    Yuan, Ting
    Ji, Weiping
    Yang, Qingcheng
    Dong, Yang
    Wang, Jieyi
    Chan, C. Hubert
    Hu, Haiyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
    Hamid, Omid
    Chiappori, Alberto A.
    Thompson, John A.
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Eskens, Ferry A. L. M.
    Ros, Willeke
    Diab, Adi
    Spano, Jean-Philippe
    Rizvi, Naiyer A.
    Wasser, Jeffrey S.
    Angevin, Eric
    Ott, Patrick A.
    Forgie, Alison
    Yang, Wenjing
    Guo, Cen
    Chou, Jeffrey
    El-Khoueiry, Anthony B.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
  • [5] Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
    Tolcher, Anthony W.
    Sznol, Mario
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos P.
    Patnaik, Amita
    Rasco, Dreww.
    Di Gravio, Donna
    Huang, Bo
    Gambhire, Dhiraj
    Chen, Ying
    Thall, Aron D.
    Pathan, Nuzhat
    Schmidt, Emmett V.
    Chow, Laura Q. M.
    CLINICAL CANCER RESEARCH, 2017, 23 (18) : 5349 - 5357
  • [6] First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
    Ku, G.
    Shen, L.
    Klempner, S. J.
    Pan, H.
    Kratz, J.
    Liang, X.
    Deng, Y.
    Kim, S.
    Wang, Z.
    Feller, L.
    Powderly, J.
    Dayyani, F.
    Schneider, R. E.
    Girda, E.
    Berlin, J. D.
    Spencer, K.
    Nguyen, M. T.
    Wang, V.
    Xu, C.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S631 - S631
  • [7] Differential effects of agonistic 4-1BB (CD137) monoclonal antibody on the maturation and functions of hypoxic dendritic cells
    Shang, Qianwen
    Dong, Zhaojing
    Liu, Chunmei
    Bai, Yang
    Guo, Chun
    Zhang, Lining
    Wang, Qun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2014, 23 (02) : 609 - 616
  • [8] First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors
    Desai, Jayesh
    Frentzas, Sophia
    Fakih, Marwan
    Ameratunga, Malaka
    O'Neill, Siobhan
    Pelster, Meredith
    Stein, Brian N.
    Body, Amy
    Li, Bai
    Strauss, Ross M.
    Zhao, Yating
    Dong, Gaohong
    Cecchini, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 123 - 123
  • [9] A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
    Xue, J.
    Sun, Y.
    Li, D.
    Guo, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S629 - S629
  • [10] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
    Ullenhag, Gustav J.
    Yachnin, Jeffrey
    Carneiro, Ana
    Elison, Emma
    Carlsson, Malin
    Russell, Charlotte Astrid
    Smith, Karin Enell
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345